APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly

David M Chascsa1, Elise M N Ferré2, Yannis Hadjiyannis2

  • 1TranslationalHepatology SectionLiver Diseases BranchNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaMD.

Abstract

Insights

APECED-associated hepatitis (APAH) is more common than previously thought and can appear before other APECED symptoms. This condition often presents mildly and responds well to treatment, with specific autoantibodies correlating to its development.

Area of Science:

  • Endocrinology
  • Hepatology
  • Immunology

Background:

  • Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is caused by AIRE mutations, leading to chronic mucocutaneous candidiasis and multisystem autoimmunity.
  • APECED-associated hepatitis (APAH) has a previously reported prevalence of ~10% in European cohorts, with varied clinical presentations.
  • This study aimed to characterize APAH in a large APECED cohort from the Americas.

Purpose of the Study:

  • To determine the prevalence and clinical characteristics of APAH in an American APECED cohort.
  • To identify factors associated with the development of APAH.
  • To compare APAH presentation with classic autoimmune hepatitis (AIH).

Main Methods:

  • Evaluation of 45 consecutive APECED patients, including hepatology consultation, liver ultrasound, and liver biopsies.
  • Assessment of hepatic and autoimmune biomarkers.
  • 16S ribosomal RNA (rRNA) sequencing of stool samples from 35 patients (12 with APAH, 23 without).

Main Results:

  • APAH was identified in 18 out of 43 (42%) evaluable patients, with 33.3% presenting before classic APECED criteria.
  • Patients with APAH showed elevated aminotransferases and/or hyperbilirubinemia, with all in clinical remission during evaluation.
  • APAH development was associated with specific autoantibodies and the homozygous c.967_979del13 AIRE mutation; stool analysis revealed higher abundance of Slackia and Acidaminococcus in APAH patients.

Conclusions:

  • APAH is more prevalent than previously reported and can precede other APECED manifestations.
  • APAH typically presents with milder, treatment-responsive disease compared to fulminant hepatic failure.
  • Specific APECED-associated autoantibodies correlate with APAH, unlike standard AIH biomarkers.